Sonofi and Sobi get Altuviiio FDA approval to treat hemophilia A
Sonofi and Sobi have secured the approval of the US Food and Drug Administration (FDA) for their Altuviiio for hemophilia A treatment. Altuviiio, previously known ... Read More
Sanofi signs $1.45bn deal to acquire Kymab, expanding its immune-therapy pipeline
In a significant move to bolster its immuno-oncology and immune-mediated disease portfolio, Sanofi has acquired Kymab, a UK-based clinical-stage biopharma company, in a deal valued ... Read More
Sanofi to acquire US biopharma company Principia Biopharma for $3.7bn
Sanofi acquisition of Principia Biopharma : French pharma giant Sanofi has signed an all-cash deal worth $3.68 billion to acquire Principia Biopharma, a late-stage California-based ... Read More
Vaccine giants Sanofi, GSK announce COVID-19 vaccine partnership
French pharma company Sanofi has announced a COVID-19 vaccine partnership with GlaxoSmithKline (GSK) to develop an adjuvanted vaccine for the novel coranavirus, by combining their ... Read More
Novartis secures EC approval for Gilenya in pediatric multiple sclerosis treatment
Novartis has announced that the European Commission has expanded the approval of its multiple sclerosis drug, Gilenya (fingolimod), to include the treatment of children and ... Read More
Spark Therapeutics’ Luxturna gains EU approval as first gene therapy for inherited retinal disease
In a significant breakthrough for treating inherited vision loss, Pennsylvania-based Spark Therapeutics has received European Commission (EC) approval for its pioneering gene therapy, Luxturna (voretigene ... Read More
Novartis to acquire AveXis for $8.7bn to expand gene therapy and neuroscience portfolio
Novartis, a Swiss pharmaceutical giant, has confirmed a substantial acquisition of AveXis, a US-based gene therapy company, for a total of $8.7 billion. This strategic ... Read More